

GLEN MILLS, PA -- March 12, 2007

RESEARCHER'S PRESENTATION SUPPORTS THE USE OF LONGPORT'S TECHNOLOGY

Longport, Inc. (OTC PK: LPTI), a medical technology specialist in high-frequency high resolution ultrasound imaging, today announced a March 7 presentation at the New Jersey Hospital Association Pressure Ulcer Collaborative by Karen Zulkowski DNS,RN, CWS supporting the use of Longport's EPISCAN. Dr Zulkowski, the principal investigator exploring the use of Longport's EPISCAN I-200 for improved clinical detection of pressure ulcer risk and development gave an overview of study progress and presented a case study. Key points outlined by Dr Zulkowski included her findings for more than 90% new admissions to the facilities had ultrasound changes consistent with tissue injury, most in the absence of overt skin changes. Furthermore, she commented, "care planning and intervention on the basis of ultrasound findings may help to differentiate avoidable versus unavoidable (pressure ulcers) pursuant to the regulatory oversight process." Of particular interest to Dr Zulkowski was how the use of the EPISCAN I-200 made an impact on nursing care when used as a teaching tool; "this is an excellent teaching tool showing the staff that there is actually something going on under the skin even though you can't see it on the surface".

Dr Zulkowski concluded her presentation by saying "early recognition of deep tissue changes is an important step in

providing pressure ulcer prevention. Ultrasound technology is now able to help identify these tissue changes before they are observable on the skin surface. Integration of ultrasound into clinical practice can help facilitate earlier care planning for pressure ulcer prevention."

Dr. Zulkowski is a professor of nursing at Montana State University-Bozeman and is an alumnus of the National Pressure Ulcer Advisory Panel (NPUAP).

Further details on this presentation and other clinical study papers can be viewed in the News section of Longport's web site:

<http://www.longportinc.com/about/news.html>

"This presentation in concert with clinical study results further validates the use of our technology for clinical acceptance and clinical use" said Connie Phillips-Jones, RN, MSN Longport's Director of Clinical Support

About Longport, Inc.

Longport, Inc. of Glen Mills, Pennsylvania, is a medical technology company that specializes in high resolution ultrasound imaging. After several years and a multi-million dollar investment in the technology, Longport has secured patents, copyrights and FDA permission to market. The Company's technology has been used to engineer a unique high resolution ultrasound imaging system. For further information please contact Longport, Inc. at 1-800-289-6863 or visit our website at www.longportinc.com.

Forward-looking Information and the Private Securities Litigation
Reform Act of 1995

Certain statements in this press release, including statements concerning product development milestones and anticipated events, are "forward-looking statements" within the Private Litigation Reform Act of 1995. Forward Looking Statements are based on the opinions and estimates of management at the time the statements are made and are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements. The words "believe," "expect," "intend," "anticipate," variations of such words, and similar expressions identify forward-looking statements, but their absence does not mean that the statement is not forward-looking. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Factors that could affect Longport's actual results include, among others, uncertainties as to the Company's ability to manage potential problems, delays or anticipated expenses, including problems, delays or expenses involving manufacturing. Readers are cautioned not to place undue reliance upon these forward-looking statements that speak only to the date of this release. Reference is made to Longport's 2004 annual report on Form 10-K filed with the Securities and Exchange Commission for a more definitive description of such factors. Longport, Inc. undertakes no obligation to update publicly any forward-looking statements to reflect new

*information, events or circumstances after the date of this
release or to reflect the occurrence of unanticipated events.*